Fatemeh Rangraz Jeddi; Mohammadreza Mobayen; Alireza Feizkhah; Razieh Farrahi; Safiyehsadat Heydari; Parissa Bagheri Toolaroud
Volume 24, Issue 5 , 2022
Abstract
Background: One of the most expensive aspects of healthcare is providing treatment for burn victims. However, just a few burn cost analysis studies have been conducted in Iran.
Objectives: This study, thus, aimed to estimate the cost of treating severe burn patients in a burn center.
Methods: This retrospective ...
Read More
Background: One of the most expensive aspects of healthcare is providing treatment for burn victims. However, just a few burn cost analysis studies have been conducted in Iran.
Objectives: This study, thus, aimed to estimate the cost of treating severe burn patients in a burn center.
Methods: This retrospective study was performed on medical records of 143 severe burn patients referred to a specialized burn center between March 2020 and March 2021. The data were collected regarding the treatment costs and were analyzed using the SPSS software (version 16.0).
Results: The mean±SD total per-patient cost was US$ 5445.53±4742.45. Electrical burn patients had a higher average total cost of care and length of stay, compared to other burn patients. Bed charges (21.97%), the surgeons salary (27.17%), as well as equipment and consumables (17.83%), were the main cost drivers.
Conclusion: The results of this study can help hospital authorities and governments understand the direct costs of a burn center and the total budget a country might need to cover the annual costs of treating burn victims. In addition, the cost of burn care in this study differed from that in other studies. The disparity in reported numbers can be attributed to variations in methodologies being used, costing viewpoints, study site, treatment procedures, hospitalization regulations, medications, surgeries, health service providers salaries, nonclinical support, and indirect costs.
Ali Khani; Farnoosh Ebrahimzadeh; Alireza Mohammadzadeh Shabestari; Parisa Eshaghizadeh; Soheila Aminzadeh; majid taati moghadam
Volume 24, Issue 4 , 2022
Abstract
Because the article is letter to editor is not needed.
Read More
Because the article is letter to editor is not needed.
Talha Karab?y?k; Durmu? Ayan; Sercan Unal
Volume 24, Issue 3 , 2022
Abstract
Background: Hepsin is known as a cell-surface serine protease expressed predominantly in the liver. Hepsin-deficient mice show resistance to high-fat diet-induced obesity, hyperlipidemia, and hyperglycemia. Up to the present, the physiological function of hepsin has not been fully determined. Hepsin ...
Read More
Background: Hepsin is known as a cell-surface serine protease expressed predominantly in the liver. Hepsin-deficient mice show resistance to high-fat diet-induced obesity, hyperlipidemia, and hyperglycemia. Up to the present, the physiological function of hepsin has not been fully determined. Hepsin may play significant and specific roles in diabetes.
Objectives: This study aimed to evaluate the relationship between hepsin protein concentrations in serum and type 2 diabetes mellitus (T2DM) and elucidate possible associations with disease activity andinflammatory and metabolic parameters. To the best of our knowledge, this is the first study evaluating the relationship between hepsin, lymphocyte-to-C-reactive protein ratio (LCR), and type 2 diabetes in humans in the existingliterature.
Methods: This case-control study included 60 patients (30 males and 30 females) diagnosed with type 2 diabetes, according to American Diabetes Association's criteria, and 30 healthy controls (14 males and 16 females) with similar demographic characteristics. Several laboratory parameters were assessed including fasting glucose, total cholesterol, insulin, hemoglobin A1c, gamma-glutamyl transferase, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, uric acid, C-reactive protein, atherogenic index of plasma, LCR, monocyte-to-neutrophil ratio,neutrophil-to-lymphocyte ratio, and serum hepsin levels.
Results: The type 2 diabetes group had significantly higher LCR than controls (P<0.016). Correlation analysis in the patient group showed a statistically significant relationship between hepsin and LCR (rho=0.296,P=0.02). Hepsin was negatively correlated with CRP in the patient group (rho=-0.333, P=0.01). Correlation analysis in the patient group showed a statistically significant relationship between hepsin and cholesterol (rho= 0.29,P= 0.02). Age was positively correlated with hepsin in the patient group (rho= 0.267, P=0.04). There was no statistically significant difference in serum hepsin levels between the diabetes group and the control group (P=0.157).
Conclusion: To the best of our knowledge, this is the first study assessing the hepsin levels in patients with T2DM. Our results indicated that increased levels of hepsin could be associated with the inflammatory processes. Similar results were not found for diabetes. However, it is recommended that similar studies should be conducted in larger patient populations.
